北美碳青霉烯类抗生素市场预测至 2028 年 - COVID-19 影响和区域分析（按类型（美罗培南、多尼培南、亚胺培南、替比培南等）、适应症（细菌性脑膜炎、急性盆腔感染、呼吸道感染、腹内感染）） 、尿路感染等）和分销渠道（零售药房、网上药房、医院药房）
No. of Pages: 144 | Report Code: TIPRE00028777 | Category: Life Sciences
No. of Pages: 144 | Report Code: TIPRE00028777 | Category: Life Sciences
市场的增长归因于细菌感染患病率上升和仿制药不断开发等驱动因素。然而，繁琐且昂贵的抗生素开发过程预计将在预测期内抑制市场的增长。
革兰氏阴性细菌感染，例如尿路感染（尿路感染（UTI）、肺炎、血流感染、伤口或手术部位感染以及脑膜炎是患者在住院期间常见的疾病。这些感染通常称为医院获得性感染 (HAI)。尿路感染和肺炎等感染在重症监护病房的患者中很常见。根据美国国家医疗安全网络的数据，30% 的 HAI 是由革兰氏阴性菌引起的，约 45% 是由尿路感染引起的，约 47% 是由呼吸机相关性肺炎 (VAP) 引起的。由革兰氏阴性菌引起的传染病的患病率正在迅速增加。
此外，革兰氏阴性细菌感染对多种药物具有耐药性，并对现有抗生素产生了更好的耐药性。抗生素耐药性（AMR）已成为现代医学的全球威胁。因此，需要对临床分离株的新趋势进行持续监测。欧洲拉脱维亚的一组研究人员研究了不同革兰氏阴性菌的 AMR 进展情况。根据他们于 2021 年 6 月在 MDPI 杂志上发表的研究文章，美罗培南和厄他培南等碳青霉烯类抗生素对革兰氏阴性菌最有效，耐药率分别为 3% 和 5.4%。这些抗生素被全球接受作为革兰氏阴性菌的治疗方法。因此，预计未来几年对碳青霉烯类抗生素的高需求可能会持续下去。
根据美国疾病控制与预防中心 (CDC) 的数据， COVID-19 大流行导致 2020 年 HAI 病例增加。全球住院人数增加，这增加了 COVID-19 患者继发感染 VAP 的风险。这导致对碳青霉烯类抗生素的需求增加，这对市场有很大帮助。
Strategic insights for North America Carbapenem-Based Antibiotics involve closely monitoring industry trends, consumer behaviours, and competitor actions to identify opportunities for growth. By leveraging data analytics, businesses can anticipate market shifts and make informed decisions that align with evolving customer needs. Understanding these dynamics helps companies adjust their strategies proactively, enhance customer engagement, and strengthen their competitive edge. Building strong relationships with stakeholders and staying agile in response to changes ensures long-term success in any market.
| Report Attribute | Details |
|---|---|
| Market size in 2021 | US$ 1,244.59 Million |
| Market Size by 2028 | US$ 1,713.21 Million |
| Global CAGR (2021 - 2028) | 4.7% |
| Historical Data | 2019-2020 |
| Forecast period | 2022-2028 |
| Segments Covered |
By 类型
|
| Regions and Countries Covered | 北美
|
| Market leaders and key company profiles |
The regional scope of North America Carbapenem-Based Antibiotics refers to the geographical area in which a business operates and competes. Understanding regional nuances, such as local consumer preferences, economic conditions, and regulatory environments, is crucial for tailoring strategies to specific markets. Businesses can expand their reach by identifying underserved regions or adapting their offerings to meet regional demands. A clear regional focus allows for more effective resource allocation, targeted marketing, and better positioning against local competitors, ultimately driving growth in those specific areas.
The North America Carbapenem-Based Antibiotics Market is valued at US$ 1,244.59 Million in 2021, it is projected to reach US$ 1,713.21 Million by 2028.
As per our report North America Carbapenem-Based Antibiotics Market, the market size is valued at US$ 1,244.59 Million in 2021, projecting it to reach US$ 1,713.21 Million by 2028. This translates to a CAGR of approximately 4.7% during the forecast period.
The North America Carbapenem-Based Antibiotics Market report typically cover these key segments-
The historic period, base year, and forecast period can vary slightly depending on the specific market research report. However, for the North America Carbapenem-Based Antibiotics Market report:
The North America Carbapenem-Based Antibiotics Market is populated by several key players, each contributing to its growth and innovation. Some of the major players include:
The North America Carbapenem-Based Antibiotics Market report is valuable for diverse stakeholders, including:
Essentially, anyone involved in or considering involvement in the North America Carbapenem-Based Antibiotics Market value chain can benefit from the information contained in a comprehensive market report.
Office No. 1011, First floor, Farena Corporate Park, Magarpatta-Mundhwa road, Pune - 411028, Maharashtra, India
US:+16467917070
sales@businessmarketinsights.com
Get Free Sample For North America Carbapenem-Based Antibiotics Market
